ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
January 15 2020 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory
authorizations to sell its patented nicotinamide riboside chloride
(NR, or Niagen®) to consumers in both the European Union and in
Australia.
ChromaDex received its listing number for Tru Niagen® on the
Australian Registry of Therapeutic Goods (ARTG) on January 8,
2020. The Company also received authorization to sell its
patented nicotinamide riboside chloride as a novel food in the
European Union on January 10, 2020. As the regulatory
applicants and innovators, ChromaDex benefits from market
exclusivity in Australia until December 2021 and market exclusivity
in the EU until February 2025.
“These regulatory notifications allow us to bring our clinically
validated Tru Niagen® to the people of Europe and Australia,” says
ChromaDex CEO Rob Fried. “We look forward to product launches
with our distribution partners in these important markets.”
Niagen® is the only commercially available NR which has twice
been successfully reviewed under U.S. Food & Drug Association's
(FDA) new dietary ingredient (NDI) notification requirement and has
also been successfully notified to the FDA as generally recognized
as safe (GRAS). ChromaDex also secured regulatory approval on its
patent-protected ingredient in Canada.
For additional information on the science supporting Niagen,
please visit www.chromadex.com.
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside
chloride, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Vice President of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024